BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
회사 코드BNTX
회사 이름Biontech SE
상장일Oct 10, 2019
설립일2019
CEOProf. Ugur Sahin, M.D.
직원 수6772
유형Depository Receipt
회계 연도 종료Oct 10
주소An der Goldgrube 12
도시MAINZ
증권 거래소NASDAQ Global Select Consolidated
국가Germany
우편 번호55131
전화4949613190840
웹사이트https://www.biontech.com/
회사 코드BNTX
상장일Oct 10, 2019
설립일2019
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음